Market closedNon-fractional

Alkermes/ALKS

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Ticker

ALKS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Dublin, Ireland

Employees

2,100

Alkermes Metrics

BasicAdvanced
$4.1B
Market cap
9.55
P/E ratio
$2.53
EPS
0.55
Beta
-
Dividend rate
$4.1B
0.55
3.126
2.451
28.786
29.496
20.00%
14.65%
50.45%
9.55
2.34
3.27
3.5
10.24
54.01%
-353.62%
18.25%
62.13%

What the Analysts think about Alkermes

Analyst Ratings

Majority rating from 13 analysts.
Buy

Alkermes Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
10.50% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$350M
-7.18%
Net income
$37M
-67.35%
Profit margin
10.50%
-64.84%

Alkermes Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 26.26%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.55
$0.64
$0.22
$0.43
-
Expected
$0.46
$0.44
$0.51
$0.58
$0.70
Surprise
19.05%
44.70%
-57.15%
-26.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Alkermes stock?

Alkermes (ALKS) has a market cap of $4.1B as of July 04, 2024.

What is the P/E ratio for Alkermes stock?

The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 9.55 as of July 04, 2024.

Does Alkermes stock pay dividends?

No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Alkermes dividend payment date?

Alkermes (ALKS) stock does not pay dividends to its shareholders.

What is the beta indicator for Alkermes?

Alkermes (ALKS) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Alkermes stock

Buy or sell Alkermes stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing